1245794-53-9Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1
-
Page/Page column 180-181, (2021/01/29)
This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)
POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS
-
Paragraph 00904, (2017/07/06)
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as toll-like receptor 7/8 (TLR7/8) antagonists. In Formula (I), Ring A is aryl or heteroaryl; Ring B is aryl or heteroary; and X is C(R4)2, O, NR4, S, S(R4), or S(R4)2.
TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
-
Paragraph 1138; 1140, (2017/01/23)
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.
3-benzyl-3-azabicyclo[3.1.1]heptan-6-one: A promising building block for medicinal chemistry
Denisenko, Aleksandr V.,Mityuk, Andrey P.,Grygorenko, Oleksandr O.,Volochnyuk, Dmytro M.,Shishkin, Oleg V.,Tolmachev, Andrey A.,Mykhailiuk, Pavel K.
supporting information; experimental part, p. 4372 - 4375 (2010/12/18)
Figure Presented. An efficient two-step multigram synthesis of the previously unknown 3-benzyl-3-azabicyclo[3.1.1]heptan-6-one is described. The compound is shown to be a promising building block for further selective derivatization of the cyclobutane ring providing novel conformationally restricted piperidine derivatives.
